← Toutes les maladies
Cancer
Cancer du poumon (à petites cellules)
Souhaites-tu recevoir une notification quand une nouvelle étude paraît sur le Cancer du poumon (à petites cellules) ? C'est possible avec un compte. Créer un compte gratuit ou se connecter.
Suivi automatiquement depuis PubMed et ClinicalTrials.gov, les plus récentes en haut. Rien ne disparaît jamais ici : ce que tu conserves dans tes favoris reste trouvable. · Flux RSS de cette maladie · uniquement les preuves les plus solides
Lire en langage simple ce que chaque étude examine ? Avec Premium, une phrase s'affiche au-dessus de chaque publication pour expliquer ce qui a été étudié — et vous recevez une notification dès qu'une nouvelle recherche est disponible sur le Cancer du poumon (petites cellules). Découvre le coût de Premium.
Publications et études (3246)
- Gut microbiota-associated nutritional-immune status predicts prognosis in postoperative NSCLC patients. (2026/12/31) ♡
- Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response. (2026/12/31) ♡
- Drug-Induced liver injury with adebrelimab: how to assess causality using the updated RUCAM? (2026/12/01) ♡
- Letter regarding 'clinicopathological characteristics and therapeutic outcomes in patients with non-small cell lung cancer harboring SMARCA4 mutations'. (2026/12/01) ♡
- Rosmarinic acid inhibits non-small cell lung cancer progression by directly targeting KRAS(G12C) and modulating the KRAS/AKT/ERK signaling axis. (2026/09/01) ♡
- Article de synthèseiUn résumé de ce que l'on sait sur un sujet, rédigé par des experts. Non élaboré selon des règles de recherche fixes, la sélection des études peut donc être biaisée. Innovative immune checkpoint modulators: monoclonal antibodies, small molecules, non-coding RNAs, and nanoparticles in cancer immunotherapy. (2026/09/01) ♡
- Systemic inflammatory response and complications developing in patients undergoing lobectomy for non-small-cell lung cancer: thoracotomy versus video-assisted thoracoscopic surgery. (2026/09/01) ♡
- Single-cell multiomics identifies an ALDH9A1-carnitine signaling axis driving resistance of NSCLC to immunotherapy. (2026/08/18) ♡
- Durvalumab Consolidation After Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety. (2026/08/10) ♡
- Construction of a survival prediction model and analysis of influencing factors for brain metastasis in non-small cell lung cancer based on multi‑parameter clinical data. (2026/08/10) ♡
- Is There Still Room for Monotherapy in EGFR-Mutated Non-Small Cell Lung Cancer? (2026/08/10) ♡
- Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. (2026/08/10) ♡
- Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR Variations in Concurrent TP53 Mutations: Research Summary. (2026/08/10) ♡
- Liquid Biopsies for Cancer: A Translational Science Review. (2026/08/10) ♡
- Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study. (2026/08/10) ♡
- MAGEA1 drives tumor progression via activation of the AKT pathway and correlates with elevated radiosensitivity in lung adenocarcinoma. (2026/08/10) ♡
- Article de synthèseiUn résumé de ce que l'on sait sur un sujet, rédigé par des experts. Non élaboré selon des règles de recherche fixes, la sélection des études peut donc être biaisée. From KRAS inhibition to tumor adaptation: mechanistic layers of resistance and therapeutic strategies. (2026/08/09) ♡
- Siglec-15 and PD-1 checkpoint blockade in combination with oncolytic Zika virus infection confers protection against immune-resistant gliomas. (2026/08/08) ♡
- Myeloperoxidase/ASGPR Dual-Targeting Self-Amplifying Nanoplatform for Synergistic Anti-Metastatic Therapy of Hepatocellular Carcinoma. (2026/08/08) ♡
- Real-World Outcomes of Consolidation Durvalumab After Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Cohort Study From Vietnam. (2026/08/08) ♡
- Exploring multidimensional cfDNA methylation fragmentomics for non-invasive postoperative assessment in early-stage lung cancer. (2026/08/08) ♡
- Association of SGLT2 Inhibitor Use with Clinical Outcomes in Patients Receiving Immune Checkpoint Inhibitors: A Pan-Tumor Propensity-Matched Analysis. (2026/08/08) ♡
- Salidroside Alleviates Mobocertinib-Induced Cardiotoxicity by Improving Cardiac Electrophysiology. (2026/08/08) ♡
- Clinical relative biological effectiveness of carbon-ion versus photon radiotherapy derived from tumor control probability models in locally advanced non-small cell lung cancer. (2026/08/08) ♡
- Deubiquitinase inhibition exposes a subtype-specific vulnerability in SCLC-P. (2026/08/07) ♡
- Lactate derived from CAFs mediates H3K18la in stemness gene promoters, which promotes tumor malignant phenotype formation. (2026/08/07) ♡
- Five-Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient-Initiated Nationwide Survey in Japan. (2026/08/07) ♡
- Genomic Landscape and Therapeutic Implications of ALK Fusion-Positive Colorectal Cancer. (2026/08/07) ♡
- Dosimetric impact of spatial separation in combined SBRT and mediastinal radiotherapy for peripheral small cell lung cancer. (2026/08/07) ♡
- Une souris transgénique tolérante aux cellules de cancer syngénéique exprimant le récepteur du facteur de croissance épidermique humain tronqué. (2026/08/07) ♡
- Examen systématiqueiToutes les études sur une question ont été recherchées selon des règles fixes et comparées, de sorte qu'aucune étude aux résultats négatifs n'a été omise. Efficacy and safety of first-line immune checkpoint inhibitors combinations for extensive-stage small-cell lung cancer: A systematic review and network meta-analysis. (2026/08/07) ♡
- Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort. (2026/08/07) ♡
- EZH1/2 inhibition selectively targets SMARCA4/2 co-deficient lung cancer cells by suppressing stemness and proliferation. (2026/08/07) ♡
- Artificial intelligence-powered evaluation of the pathologic response to preoperative therapy in non-small cell lung cancer. (2026/08/07) ♡
- [Sauvetage des résections en chirurgie thoracique pour les carcinomes pulmonaires septiques subissant une thérapie systémique: une série de cas]. (2026/08/07) ♡
- Clonal LIMD1 loss drives PD-L1 immune evasion via ARIH1-dependent ubiquitination in lung cancer. (2026/08/07) ♡
- Article de synthèseiUn résumé de ce que l'on sait sur un sujet, rédigé par des experts. Non élaboré selon des règles de recherche fixes, la sélection des études peut donc être biaisée. Small-Cell Lung Cancer: Biology, Translational Science and Clinical Innovation. (2026/08/07) ♡
- Engineering Rigid Nanocarriers to Enhance Photothermal Performance for Suppressing Breast Cancer and Pulmonary Metastasis. (2026/08/07) ♡
- Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. (2026/08/07) ♡
- Immune signatures in NSCLC associated pleural effusions and implications for prognosis. (2026/08/07) ♡
- Efficacy and Safety of Sintilimab in Combination With Anlotinib and Chemoradiotherapy as First-Line Treatment for Driver Gene-Negative Oligometastatic Non-small Cell Lung Cancer: A Real-World Cohort Study. (2026/08/07) ♡
- Agent-Based Simulations of Lung Tumor Evolution Suggest That Ongoing Cell Competition Drives Realistic Clonal Expansions. (2026/08/06) ♡
- Diabetes Increases Immunotherapy-Related Toxicity but Not Efficacy in Metastatic Non-Small Cell Lung Cancer: A Multicenter Retrospective Study. (2026/08/06) ♡
- Beyond the clinical trial: Real-world treatment patterns and drivers of PD-(L)1 therapy use in first-line metastatic NSCLC. (2026/08/06) ♡
- Targeting the METTL14/Wnt9a/β-catenin pathway with pharmacological inhibitors enhances radiotherapy and immunotherapy efficacy in non-small cell lung cancer. (2026/08/06) ♡
- Article de synthèseiUn résumé de ce que l'on sait sur un sujet, rédigé par des experts. Non élaboré selon des règles de recherche fixes, la sélection des études peut donc être biaisée. A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC. (2026/08/06) ♡
- SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation. (2026/08/06) ♡
- Article de synthèseiUn résumé de ce que l'on sait sur un sujet, rédigé par des experts. Non élaboré selon des règles de recherche fixes, la sélection des études peut donc être biaisée. Biomarker-Driven Insights into Immune Checkpoint Inhibitor Therapy in Small-Cell Lung Cancer. (2026/08/06) ♡
- Hypoxia-activated endothelial cells drive stemness and vasculogenic mimicry in NSCLC via a HIF-1α/ITPR3 axis. (2026/08/06) ♡
- De-escalation of Adjuvant EGFR-TKI in Stage IB EGFR-Mutated Non-small-cell Lung Cancer: A Real-World Study. (2026/08/06) ♡
codex.care ne donne pas de conseils médicaux. Discute toujours des plaintes, des médicaments et des choix de traitement avec ton propre médecin.